\
&
Contact us
\
&
Contact us
Published on | 6 years ago
Programmes COST COSTThe COST Association is launching the COST Innovators’ Grant (CIG) pilot scheme.
The COST Innovators’ Grant aims at enhancing the pace and success of breakthrough innovations, to build bridges between the scientific research performed in COST Actions and marketable applications and/or societal solutions and to explore innovation potential. For those COST Actions which demonstrate commercial/innovation potential, an additional budget will be allocated. The funding will cover the activities required to turn the research network outputs into either a commercial or technical proposition. To fully benefit from this Innovators Grant and successfully implement it, COST Actions will be able to apply for a one-year add on of their activities.
This pilot scheme is open for ending Actions selected for funding under OC-2015-1, which finish before 31 May 2020. The COST Innovators’ Grant activities funded under the pilot scheme will run from 1 May 2020 until 30 April 2021.
To read the full COST press release please click here.
More information on the CIGs and the application procedure can be found in the guidelines available here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
